Literature DB >> 21466803

Dopamine D(3) receptor antagonist SB-277011A inhibits methamphetamine self-administration and methamphetamine-induced reinstatement of drug-seeking in rats.

Amanda E Higley1, Stephen W Kiefer, Xia Li, József Gaál, Zheng-Xiong Xi, Eliot L Gardner.   

Abstract

We have previously reported that selective blockade of brain dopamine D(3) receptors by SB-277011A significantly attenuates cocaine self-administration and cocaine-induced reinstatement of drug-seeking behavior. In the present study, we investigated whether SB-277011A similarly inhibits methamphetamine self-administration and methamphetamine-induced reinstatement to drug-seeking behavior. Male Long-Evans rats were allowed to intravenously self-administer methamphetamine (0.05 mg/kg/infusion) under fixed-ratio 2 (FR2) or progressive-ratio (PR) reinforcement conditions, and some rats were tested for methamphetamine-induced reinstatement of drug-seeking behavior after extinction of self-administration. The effects of SB-277011A on each of these methamphetamine-supported behaviors were then tested. Acute intraperitoneal (i.p.) administration of SB-277011A failed to alter methamphetamine self-administration under FR2 reinforcement, but significantly lowered the break-point for methamphetamine self-administration under PR reinforcement. SB-277011A also significantly inhibited methamphetamine-triggered reinstatement of extinguished drug-seeking behavior. Overall, these data show that blockade of dopamine D(3) receptors by SB-277011A attenuates the rewarding and incentive motivational effects of methamphetamine in rats, supporting the development of selective dopamine D(3) antagonists for the treatment of methamphetamine addiction. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21466803      PMCID: PMC3728376          DOI: 10.1016/j.ejphar.2011.02.046

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  54 in total

Review 1.  What we have learned about addiction from animal models of drug self-administration.

Authors:  E L Gardner
Journal:  Am J Addict       Date:  2000

2.  Stress and relapse to drug seeking in rats: studies on the generality of the effect.

Authors:  U Shalev; D Highfield; J Yap; Y Shaham
Journal:  Psychopharmacology (Berl)       Date:  2000-06       Impact factor: 4.530

3.  Acute administration of the selective D3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats.

Authors:  Charles R Ashby; Mousumi Paul; Eliot L Gardner; Christian A Heidbreder; Jim J Hagan
Journal:  Synapse       Date:  2003-06-01       Impact factor: 2.562

4.  Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats.

Authors:  Stanislav R Vorel; Charles R Ashby; Mousumi Paul; Xinhe Liu; Robert Hayes; Jim J Hagan; Derek N Middlemiss; Geoffrey Stemp; Eliot L Gardner
Journal:  J Neurosci       Date:  2002-11-01       Impact factor: 6.167

Review 5.  Pathways to relapse: the neurobiology of drug- and stress-induced relapse to drug-taking.

Authors:  J Stewart
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

6.  PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats.

Authors:  Amanda E Higley; Krista Spiller; Peter Grundt; Amy Hauck Newman; Stephen W Kiefer; Zheng-Xiong Xi; Eliot L Gardner
Journal:  J Psychopharmacol       Date:  2010-02-08       Impact factor: 4.153

Review 7.  How does stress increase risk of drug abuse and relapse?

Authors:  R Sinha
Journal:  Psychopharmacology (Berl)       Date:  2001-10-26       Impact factor: 4.530

8.  Cocaine-seeking behavior in response to drug-associated stimuli in rats: involvement of D3 and D2 dopamine receptors.

Authors:  L Cervo; F Carnovali; J A Stark; T Mennini
Journal:  Neuropsychopharmacology       Date:  2003-04-02       Impact factor: 7.853

9.  Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.

Authors:  C Reavill; S G Taylor; M D Wood; T Ashmeade; N E Austin; K Y Avenell; I Boyfield; C L Branch; J Cilia; M C Coldwell; M S Hadley; A J Hunter; P Jeffrey; F Jewitt; C N Johnson; D N Jones; A D Medhurst; D N Middlemiss; D J Nash; G J Riley; C Routledge; G Stemp; K M Thewlis; B Trail; A K Vong; J J Hagan
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

10.  Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A.

Authors:  Patricia Di Ciano; Rachel J Underwood; Jim J Hagan; Barry J Everitt
Journal:  Neuropsychopharmacology       Date:  2002-06-18       Impact factor: 7.853

View more
  34 in total

1.  Selection of sucrose concentration depends on the effort required to obtain it: studies using tetrabenazine, D1, D2, and D3 receptor antagonists.

Authors:  Marta Pardo; Laura López-Cruz; Noemí San Miguel; John D Salamone; Mercè Correa
Journal:  Psychopharmacology (Berl)       Date:  2015-02-03       Impact factor: 4.530

Review 2.  Dopamine and addiction: what have we learned from 40 years of research.

Authors:  Marcello Solinas; Pauline Belujon; Pierre Olivier Fernagut; Mohamed Jaber; Nathalie Thiriet
Journal:  J Neural Transm (Vienna)       Date:  2018-12-19       Impact factor: 3.575

3.  Effects of pramipexole on the acquisition of responding with opioid-conditioned reinforcement in the rat.

Authors:  Jeremiah W Bertz; Jianyong Chen; James H Woods
Journal:  Psychopharmacology (Berl)       Date:  2014-07-03       Impact factor: 4.530

4.  Direct regulation of diurnal Drd3 expression and cocaine reward by NPAS2.

Authors:  Angela R Ozburn; Edgardo Falcon; Alan Twaddle; Alexandria L Nugent; Andrea G Gillman; Sade M Spencer; Rachel N Arey; Shibani Mukherjee; James Lyons-Weiler; David W Self; Colleen A McClung
Journal:  Biol Psychiatry       Date:  2014-08-13       Impact factor: 13.382

5.  Investigating Methamphetamine Craving Using the Extinction-Reinstatement Model in the Rat.

Authors:  Peter R Kufahl; M Foster Olive
Journal:  J Addict Res Ther       Date:  2011-11-15

Review 6.  Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.

Authors:  Christian Heidbreder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-28       Impact factor: 3.000

Review 7.  Neuronal circuitry underlying the impact of D3 receptor ligands in drug addiction.

Authors:  Bernard Le Foll; Patricia Di Ciano
Journal:  Eur Neuropsychopharmacol       Date:  2014-09-16       Impact factor: 4.600

8.  The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents.

Authors:  Chloe J Jordan; Bree Humburg; Myra Rice; Guo-Hua Bi; Zhi-Bing You; Anver Basha Shaik; Jianjing Cao; Alessandro Bonifazi; Alexandra Gadiano; Rana Rais; Barbara Slusher; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-08       Impact factor: 5.250

9.  Effects of Environmental Manipulations and Treatment with Bupropion and Risperidone on Choice between Methamphetamine and Food in Rhesus Monkeys.

Authors:  Matthew L Banks; Bruce E Blough
Journal:  Neuropsychopharmacology       Date:  2015-03-06       Impact factor: 7.853

10.  Efficacy of buspirone for attenuating cocaine and methamphetamine reinstatement in rats.

Authors:  Keith L Shelton; Elizabeth S Hendrick; Patrick M Beardsley
Journal:  Drug Alcohol Depend       Date:  2013-01-29       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.